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Patients With Dilated Cardiomyopathy
Masakazu Kobayashi, MD,* Hideo Izawa, MD, PHD,* Xian Wu Cheng, MD, PHD,†
Hiroyuki Asano, MD,* Akihiro Hirashiki, MD, PHD,* Kazumasa Unno, MD,*
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Tatsuaki Matsubara, MD, PHD,§ Toyoaki Murohara, MD, PHD,*
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Nagoya, Japan
O B J E C T I V E S We performed dobutamine stress testing for evaluation of myocardial contractile
reserve in asymptomatic or mildly symptomatic patients with dilated cardiomyopathy (DCM).
B A C KG ROUND Catecholamine sensitivity is reduced in failing hearts as a result of myocardial
abnormalities in the beta-adrenergic receptor signaling pathway. However, little is known about
adrenergic myocardial contractile reserve in asymptomatic or mildly symptomatic patients with DCM.
METHOD S The maximal ﬁrst derivative of left ventricular pressure (LV dP/dtmax) was determined during
infusion of dobutamine (10 g kg1 min1) in 46 asymptomatic or mildly symptomatic (New York Heart
Association functional class I or II) patients with DCM. The expression of messenger ribonucleic acid (mRNA)
for contractile regulatory proteins in endomyocardial biopsy specimens was quantiﬁed by reverse transcrip-
tion and real-time polymerase chain reaction analysis. Plasma norepinephrine levels were measured in all
patients and [123I]metaiodobenzylguanidine (MIBG) scintigraphy performed.
R E S U L T S Patients were classiﬁed into 3 groups based on the percentage increase in LV dP/dtmax
induced by dobutamine (∆LV dP/dtmax) and on LV ejection fraction (LVEF) at baseline: group I (n 18): ∆LV
dP/dtmax100% and LVEF25%; group IIa (n 17): ∆LV dP/dtmax100% and LVEF 25%; and group IIb
(n  11): ∆LV dP/dtmax 100% and LVEF 25%. The amounts of beta1-adrenergic receptor, sarcoplasmic
reticulum Ca2-adenosine triphosphatase, and phospholamban mRNA were signiﬁcantly smaller in groups
IIa and IIb than in group I. The plasma norepinephrine level was increased and the delayed heart/
mediastinum count ratio in MIBG scintigraphy was decreased in both groups IIa and IIb.
CONC L U S I O N S Dobutamine stress testing is a useful diagnostic tool for identifying reduced adrenergic
myocardial contractile reserve related to altered myocardial expression of beta1-adrenergic receptor, sarcoplasmic
reticulum Ca2-adenosine triphosphatase, and phospholamban genes even in asymptomatic or mildly symptom-
atic patients with DCM. (J Am Coll Cardiol Img 2008;1:718–26) © 2008 by the American College of Cardiology
Foundation
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719ilated cardiomyopathy (DCM) is character-
ized by progressive left ventricular (LV)
dilation and greatly impaired LV systolic
function. In spite of progress in pharmaco-
herapy for end-stage heart failure, the overall
rognosis of individuals with DCM is still poor. It
s therefore important that DCM patients who are
efractory to standard medical treatment be placed
nder strict management as early as possible.
See page 727
Catecholamine sensitivity is reduced in failing
earts as a result of myocardial abnormalities in the
eta-adrenergic receptor (AR) signaling pathway,
ost prominently down-regulation of the beta1-AR
1,2). Dobutamine is a relatively selective beta1-AR
gonist with weak beta2- and alpha-AR agonistic
ctivity. Dobutamine stress testing (DST) is per-
ormed widely, mostly in patients with coronary
rtery disease, to assess myocardial viability, and its
afety has been well established (3,4). Previous
tudies have determined myocardial contractile re-
erve in DCM patients by DST and found that the
esponse to dobutamine is associated with clinical
rognosis (5–7). Although the mechanisms respon-
ible for this association have remained unclear, it is
ossible that adrenergic myocardial contractile re-
erve revealed by DST reflects molecular biological
hanges in the myocardium.
We have now evaluated DST as a diagnostic tool
or identifying individuals with a reduced adrenergic
yocardial contractile reserve among patients with
CM and a New York Heart Association (NYHA)
unctional class of I or II. We have also examined the
elations of such adrenergic myocardial contractile
eserve to activity of the sympathetic nervous system
nd to myocardial expression of genes for contractile
egulatory proteins related to beta-AR signaling or
ntracellular Ca2 handling.
E T H O D S
atients. The study protocol was approved by the
thics Review Board of Nagoya University School
f Medicine (approval #359), and written informed
onsent was obtained from all study participants.
e studied 46 DCM patients with a NYHA
unctional class of I or II. Dilated cardiomyopathy
as defined by a left ventricular ejection fraction
LVEF) of 50% (as determined by contrast ven-
riculography) in the absence of coronary artery
tenosis of 50% (as determined by coronary an- diography), valvular heart disease, arterial hyperten-
ion, and cardiac muscle disease secondary to any
nown systemic condition (8). Endomyocardial bi-
psy at the LV posterior wall was performed to
xclude myocarditis or specific heart muscle disease.
ll patients were in normal sinus rhythm.
The patients were hospitalized for examinations
nd underwent laboratory measurements including
eurohumoral factors, echocardiography, resting
yocardial [123I]metaiodobenzylguanidine (MIBG)
cintigraphy, and cardiac catheterization. Fourteen
atients had been treated with beta-blockers, 11
ith digitalis, 34 with diuretics, and 33 with
ngiotensin-converting enzyme inhibitors or angio-
ensin II receptor blockers (or both). All medica-
ions were discontinued at least 4 days
efore the study. Sixteen patients had been
ospitalized because of heart failure with
yspnea on exertion or peripheral edema,
ut they had been in a stable condition for
t least 3 months and were classified as
YHA functional class II at the time of
ospitalization for the study.
yocardial [123I]MIBG scintigraphy. Myo-
ardial [123I]MIBG scintigraphic imaging
as performed as previously described (9).
dose of 148 MBq of [123I]MIBG was
njected intravenously with the patient in a
upine position. Myocardial [123I]MIBG
ptake was quantified in anterior planar
iews at 15 min (early image) and 4 h
delayed image) after tracer injection.
he heart/mediastinum count ratio was
etermined from the delayed anterior
lanar [123I]MIBG image. The washout
ate was calculated with the following
ormula: 100%  [(H  M)early  (H 
)delayed]/(H  M)early, where H is the
ean counts per pixel in the left ventri-
le and M is the mean counts per pixel in the
pper mediastinum. In our laboratory, the normal
ange for the delayed heart/mediastinum count
atio is 1.8 to 2.7 and that for the washout rate is
6% to 27%.
ardiac catheterization. All patients initially under-
ent routine diagnostic left and right heart cathe-
erization by the femoral approach. A 6-F fluid-
lled pigtail catheter with a high-fidelity
icromanometer (CA-61000-PLB Pressure-tip
atheter, CD Leycom, Zoetermeer, the Nether-
ands) was placed in the LV cavity for measurement
f LV pressure. We evaluate the maximal first
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720f contractility and the pressure half-time (T1/2) as
n index of isovolumic relaxation as previously
escribed (10). After collection of baseline hemo-
ynamic data, dobutamine was infused intrave-
ously at incremental doses of 5 and 10 g kg1
in1, and hemodynamic measurements were
ade at the end of each 10-min infusion period.
fter hemodynamic values had returned to baseline,
ndomyocardial biopsy was performed. Several (at
east 3) endomyocardial biopsy specimens for mes-
enger ribonucleic acid (mRNA) analysis were fro-
en immediately in liquid nitrogen and stored at
80°C until the analysis.
uantitative reverse transcription–polymerase chain
eaction analysis. Total RNA was isolated from 1 to
.5 mg of frozen LV biopsy specimens and subjected
o quantitative reverse transcription and polymerase
hain reaction analysis, as previously described
10,11), with primers and TaqMan probes (Nippon
GT Co. Ltd., Toyama, Japan) specific for human
omplementary DNA encoding beta1-AR, beta2-AR,
arcoplasmic reticulum Ca2-adenosine triphos-
hatase 2a (SERCA2a), phospholamban, ryanodine
eceptor-2, calsequestrin, and the Na/Ca2 ex-
hanger. The primer sequences (forward and reverse,
espectively) for G-protein–coupled receptor kinase 2
GRK2) and for the alpha subunits of Gs and Gi2 (Gs
lpha, Gi2 alpha) were as follows: GRK2, 5=-
GAGAGCGATAAGTTCACACGG-3= and 5=-
GCTTTTTGTCCAGGCACT-3=; Gs alpha, 5=-
TACTCCCTGGACAAGATCGACG-3= and
0
50
100
150
200
250
25 30 40 50
LVEF (%)
tween Baseline LVEF and LV dP/dtmax
entage change in maximal ﬁrst derivative of left ventricular pres-
dP/dtmax]) induced by intravenous infusion of dobutamine (10
nts were classiﬁed into 3 groups: group I (orange with black cir-
tmax 100% (left ventricular ejection fraction [LVEF] 25%); group IIa
), ∆LV dP/dtmax 100% and LVEF 25%; and group IIb (brown tri-e
/dtmax 100% and LVEF 25%.=-GCAGTCACATCGTTGAAGCACT-3=; and
i2alpha, 5=-GGAATACCAGCTCAACGA-
TCA-3= and 5=-CTGACCACCCACATC-
AACATCT-3=. The amount of each mRNA was
hus determined with a fluorogenic 5=-nuclease poly-
erase chain reaction assay and an ABI PRISM 7700
equence detector (Applied Biosystems, Foster City,
alifornia). All determinations were performed in
riplicate. The abundance of each mRNA was
ormalized by the corresponding amount of
lyceraldehyde-3-phosphate dehydrogenase mRNA.
tatistical analysis. Data are presented as means 
tandard deviation. For comparisons among groups,
-way analysis of variance was used for continuous
ariables when appropriate and contingency table
nalysis was used for categorical variables. Given
hat the plasma concentration of brain natriuretic
eptide was not normally distributed, we assessed
ifferences in such values with the nonparametric
ruskal-Wallis test. When a significant difference
as detected, intergroup comparisons were per-
ormed with Bonferroni’s multiple comparison test.
p value of 0.05 was considered statistically
ignificant.
E S U L T S
atient classiﬁcation. Patients were divided into
roups on the basis of the adrenergic myocardial
ontractile response revealed by DST, specifically
he percentage change in LV dP/dtmax during
obutamine infusion at a dose of 10 g kg1 min1
elative to the baseline value. Those who showed an
ncrease of 100% were assigned to group I (n 
8), and those who showed an increase of 100%
ere assigned to group II (n 28). In addition, the
atients in group II were further assigned to 2
ubgroups according to the LVEF at baseline: those
ith an LVEF of 25% (group IIa, n  17) and
hose with an LVEF of 25% (group IIb, n  11).
ll of the patients in group I had an LVEF of
25% at baseline (Fig. 1).
aseline data. Baseline clinical characteristics of the
atients are shown in Table 1. The LVEF was
ignificantly decreased in group IIb compared with
hat in group I or in group IIa, which is consistent
ith the criterion for subgroup classification. The
lasma concentration of brain natriuretic peptide
as significantly higher in group IIb than in either
f the other 2 groups. Although there were no
ignificant differences in the plasma concentration
f this peptide or in resting cardiac function as20
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Figure 1. Relation Be
We calculated the perc
sure (LV dP/dtmax [∆LV
g kg1 min1). Patie
cles, n  18), ∆LV dP/d
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721zation between groups I and IIa, the plasma
orepinephrine level was significantly higher (Fig.
) and the delayed heart/mediastinum count ratio
as significantly lower (Fig. 3) in group IIa than in
roup I.
emodynamic response to intravenous dobutamine.
o complications occurred in any of the study
ubjects during the dobutamine stress protocol. The
ffects of intravenous dobutamine infusion on he-
odynamics are shown in Table 2. The heart rate at
aseline was significantly higher in group IIb than
n group I, although that at a dobutamine infusion
ate of 10 g kg1 min1 was similar among the 3
roups. There were no significant differences in LV
P/dtmax or T1/2 among the 3 groups at baseline.
owever, LV dP/dtmax was significantly higher in
roup I than in group IIa or in group IIb at
obutamine infusion rates of 5 or 10 g kg1
in1, and T1/2 was significantly greater in group
Ib than in group I at a dobutamine infusion rate of
0 g kg1 min1.
Myocardial [123I]MIBG scintigraphy and the
hanges in LV dP/dtmax during dobutamine infu-
ion of 2 typical cases are presented in Figures 4
nd 5.
xpression of contractile regulatory protein genes.
he amount of beta1-AR mRNA was significantly
educed in group IIa and in group IIb compared
ith that in group I (Table 3). There were no
ignificant differences in the expression of beta2-
R, GRK2, Gs alpha, and Gi2 alpha genes among
he 3 groups. With regard to intracellular Ca2-
andling proteins, the abundance of SERCA2a
nd phospholamban mRNAs was significantly
educed in group IIa and in group IIb compared
ith that in group I. The abundance of ryanodine
eceptor-2, calsequestrin, and Na/Ca2 exchanger
RNAs did not differ significantly among the 3
roups.
I S C U S S I O N
he main findings of the present study include the
ollowing: 1) All patients with severe LV systolic
ysfunction (LVEF 25%) showed a reduced ad-
energic myocardial contractile reserve. 2) In some
atients with mild to moderate LV systolic dysfunc-
ion (25  LVEF 50%), adrenergic myocardial
ontractile reserve was preserved, whereas in others
t was reduced. 3) The abundance of mRNA not
nly for the beta1-AR but also for SERCA2a and
hospholamban was reduced in patients with re-
uced adrenergic myocardial contractile reserve,ven in those in whom LV systolic dysfunction was
nly mild to moderate, like that in the comparison
roup.
valuation of myocardial contractile reserve. Deter-
inants of myocardial contractile reserve include
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Figure 2. Comparison of Plasma NE Levels Among the 3 Patient
Plasma norepinephrine (NE) levels measured at baseline were signiﬁ
group IIa and in group IIb compared with that in group I. Data for
Table 1. Characteristics of the 3 Patient Groups at Baseline
Characteristic
Group I
(n  18)
Group I
(n  17
Age (yrs) 51 9 52 13
Gender, male/female 12/6 13/4
NYHA functional class I/II 10/8 8/9
Medication, n (%)
Digitalis 3 (17%) 3 (18%
Diuretics 10 (56%) 13 (76%
ACE inhibitors or ARBs 13 (72%) 14 (82%
Beta-blockers 4 (22%) 5 (29%
Spironolactone 6 (33%) 6 (35%
LV end-diastolic dimension (mm) 59 4 60 9
LV end-systolic dimension (mm) 47 5 50 10
IVS thickness (mm) 9 1 9 2
LVPW thickness (mm) 9 1 9 2
LVEF (%) 41 7 39 6
LV end-diastolic pressure (mm Hg) 17 5 15 7
PAWP (mm Hg) 11 4 11 4
Cardiac index (l min1 m2) 3.1 0.5 3.0 0.
Plasma BNP (pg/ml) 59 76 140 14
Plasma norepinephrine (pg/ml) 403 143 693 29
Delayed H/M ratio 1.9 0.2 1.6 0.
Washout rate (%) 24.7 12.6 35.6 16
Data are means  SD. *p  0.05 versus group I; †p  0.05 versus group IIa.
ACE  angiotensin-converting enzyme; ARB  angiotensin II receptor blocke
peptide; H/M  heart/mediastinum; IVS  interventricular septum; LV  left
ventricular ejection fraction; LVPW  left ventricular posterior wall; NYHA  Ne
PAWP  pulmonary arterial wedge pressure.p IIb
Groups
cantly higher in
individual subjectsIa
)
Group IIb
(n  11)
50 15
9/2
2/9
) 5 (45%)
) 11 (100%)*
) 6 (55%)
) 5 (45%)
) 7 (64%)
72 13*†
65 13*†
8 2
9 2
21 2*†
18 9
17 8*†
7 2.7 0.5
7 421 442*†
3* 655 267*
3* 1.5 0.3*
.6 42.8 15.4*
r; BNP  brain natriuretic
ventricular; LVEF  left
w York Heart Association;and the corresponding mean  SD values are shown.
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722he Frank-Starling mechanism, the force-frequency
ffect, and adrenergic stimulation (12,13). The
yocardial contractile response to adrenergic stim-
lation is impaired in DCM. Several studies based
n dobutamine stress echocardiography have dem-
nstrated a relation between prognosis and adren-
rgic myocardial contractile reserve, as determined
y measurement of indices of LV systolic function
P < 0.05
P < 0.05
Group I Group IIa Group IIb
of the Delayed H/M Ratio in [123I]MIBG Scintigraphy Among
art/mediastinum (H/M) count ratio from the delayed planer
anidine (MIBG) image. The delayed H/M ratio was signiﬁcantly
in group IIb compared with that in group I. Data for individual
sponding mean  SD values are shown.
ic Response of the 3 Patient Groups to Intravenous
r Group I Group IIa Group IIb
69 7 76 12 86 13*
g1 min1) 75 10 82 16 90 13*
kg1 min1) 98 14 98 20 99 16
122 15 113 16 112 26
g1 min1) 137 21 123 17* 115 23*
kg1 min1) 133 16 123 16 124 27
)
1131 178 1053 190 1048 224
g1 min1) 1746 298 1340 246* 1193 247*
kg1 min1) 2741 417 1692 300* 1544 342*
41 6 43 8 44 5
g1 min1) 35 8 37 10 41 5
kg1 min1) 25 5 29 11 34 7*
 0.05 versus group I.
ﬁrst derivative of left ventricular pressure; LVSP  left ventricular systolictalf-time.uch as LVEF or cardiac output (5,6). However,
hese indices are relatively load-dependent. Few
tudies have evaluated the adrenergic contractile
esponse to dobutamine infusion by measurement
f the increase in LV dP/dtmax in patients with
onischemic LV systolic dysfunction (7,14). These
tudies applied dobutamine stress with atrial pacing
r intracoronary dobutamine infusion to avoid the
ffects of a change in heart rate. In the present
tudy, we evaluated adrenergic myocardial contrac-
ile reserve on the basis of the percentage change in
V dP/dtmax at an intravenous dobutamine infusion
ate of 10 g kg1 min1, with a cutoff of 100%
ased on the median value for patients with mild to
oderate LV systolic dysfunction (25  LVEF
50%). Differences in the increase in heart rate
mong the 3 groups may have influenced the
hange in LV dP/dtmax; patient classification in our
tudy was therefore based on the frequency-
ependent inotropic response to dobutamine infu-
ion, which is clinically more useful as a measure of
drenergic myocardial functional reserve.
End-systolic wall stress as assessed by echocardi-
graphy has been shown to be a quantitative index
f true myocardial afterload and an important
eterminant of systolic function independent of
oading conditions (15). Twenty-three of the 46
atients in the present study (6, 10, and 7 patients
n groups I, IIa, and IIb, respectively) underwent
chocardiography during DST. The percentage in-
rease in end-systolic wall stress determined by
chocardiography during dobutamine infusion
ended to be higher in group I than in group IIa or
n group IIb (data not shown).
elation of altered expression of contractile regulatory
rotein genes to adrenergic myocardial contractile
eserve. The failing human heart is characterized
y a reduced sensitivity to beta-AR agonists,
hich may contribute to the loss of cardiac
ontractility (1,2,14). The decrease in cardiac
esponsiveness to beta1-AR stimulation appears
o be due in part to a reduction in the number of
eta1-ARs (14), which in turn is thought to result
rom a reduction in the amount of the corre-
ponding mRNA (16,17). Our results now sug-
est that evaluation of adrenergic myocardial
ontractile reserve by DST might be a means of
dentifying down-regulation of the beta1-AR in
atients with DCM. On the other hand, we did
ot detect changes in the abundance of GRK2 or
i2alpha mRNAs in patients with a reduced
drenergic myocardial contractile reserve, al-D
el
ay
ed
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the 3 Patient Groups
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lower in group IIa andTable 2. Hemodynam
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Paramete
Heart rate (beats/min)
Baseline
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LVSP (mm Hg)
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Baseline
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723enes was previously found to be increased in the
eart of patients with end-stage heart failure
17,18). This apparent discrepancy might be
xplained by differences in the patient popula-
ions of the studies, with our study including a
ess severely afflicted ambulatory population of
atients with a NYHA functional class of I or II.
The amounts of SERCA2a and phospholam-
an mRNAs were found to be decreased in
ndomyocardial biopsy specimens from patients
ndergoing heart transplantation (19 –21). We
reviously showed that a reduction in the myo-
ardial abundance of SERCA2a mRNA was
pparent in patients with impaired myocardial
ontractile reserve, as revealed by determination
f the force-frequency relation, before the onset
f detectable LV systolic dysfunction (10). As far
s we are aware, however, the relation between
drenergic myocardial contractile reserve and the
bundance of mRNAs for Ca2-handling pro-
eins has not previously been examined. We have
ow shown that a reduction in adrenergic myo-
ardial contractile reserve appears to be associated
ith down-regulation not only of beta1-AR
RNA but also of SERCA2a and phospholam-
an mRNAs, even in asymptomatic or mildly
ymptomatic patients with DCM. On the other
and, we did not detect changes in the abundance
f ryanodine receptor-2, calsequestrin, or Na/
a2 exchanger mRNA in patients with a re-
uced adrenergic myocardial contractile reserve,
hich may be considered consistent with previ-
us findings (21–23).
lasma norepinephrine level and quantitative
123I]MIBG scintigraphy parameters. In heart failure,
ncreased cardiac spillover of norepinephrine and
epletion of myocardial catecholamine result in
n increased plasma concentration of norepi-
ephrine (24) and decreased cardiac uptake of
123I]MIBG, an analog of norepinephrine (25).
n addition, both the plasma norepinephrine level
26) and [123I]MIBG imaging (27) have been
ound to provide prognostic information in pa-
ients with heart failure. We previously showed
hat decreased [123I]MIBG uptake in DCM pa-
ients was associated with a reduced myocardial
ontractile reserve as evaluated by atrial pacing
9). In the present study, all patients with a
reatly increased plasma level of norepinephrine
nd a greatly reduced [123I]MIBG uptake had a
educed adrenergic myocardial contractile re-
erve. However, there was marked overlap in aoderately increased levels of plasma norepi-
ephrine or moderately reduced levels of
123I]MIBG uptake among patient groups with
educed or preserved adrenergic myocardial con-
ractile reserve. These findings suggest that these
esting parameters alone do not fully reflect
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724linical implications. We have evaluated adrenergic
yocardial contractile reserve as revealed by DST
n DCM patients with a NYHA functional class
f I or II. Even among such asymptomatic or
ildly symptomatic patients, those individuals
ith a reduced adrenergic myocardial contractile
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t was a 58-year-old woman in New York Heart Association func-
II, and she had an LVEF of 42% and a plasma norepinephrine
00 pg/ml. (A) Increased lung uptake and severely reduced myo-
ake are observed, and the delayed H/M ratio was 1.3. (B) The
p between dobutamine infusion rate and LV dP/dtmax of this
hown. The LV dP/dtmax at baseline and at a dobutamine infusion
g kg1 min1 were 1,089 and 1,791 mm Hg/s, respectively (∆LV
64%). Abbreviations as in Figures 1 and 3.eserve also manifested activation of the sympa- phetic nervous system as well as altered myocar-
ial expression of the genes for the beta1-AR,
ERCA2a, and phospholamban. Our results sug-
est that DST is able to identify functional and
olecular remodeling associated with overactiva-
ion of the sympathetic nervous system in asymp-
omatic or mildly symptomatic patients with
CM, even when resting parameters still show
ormal values.
Pharmacological agents that reduce adrenergic
yperactivity, such as beta-blockers or angiotensin-
onverting enzyme inhibitors, may improve ad-
energic myocardial contractile reserve, given that
hey have been shown to induce up-regulation of
yocardial beta-ARs or recovery of the cardiac
drenergic nervous system (28 –30). Detrimental
hanges in cardiac gene expression in patients
ith DCM have also been shown to be reversed
y treatment with beta-blockers (31,32). Al-
hough further studies will be necessary to clarify
hether abnormalities of intracellular signal
ransduction related to myocardial contractility
nfluence the prognosis of asymptomatic or
ildly symptomatic patients with DCM, DST
ay provide valuable information for manage-
ent of these patients.
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725vance of DST in DCM remains unclear and
eserves further investigation.
O N C L U S I O N S
he present study suggests that DST is a useful
iagnostic tool for identifying reduced adrenergic
yocardial contractile reserve related to altered
yocardial expression of the beta1-AR, SERCA2a,
nd phospholamban genes even in asymptomatic or
ildly symptomatic patients with DCM.
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acid; SERCA2a  sarcoplasmic reticulum Ca -adenosine triphosphatase 2a.1
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